After ataxia withdrawal, Santhera considers strategic moves. Santhera Pharmaceuticalsnews release,
February 28, 2013
Thursday, February 28, 2013
What is the cost of rare diseases such as Friedreich's Ataxia?
What is the cost of rare diseases such as Friedreich's Ataxia?. Medical Xpress, February 27, 2013
What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central's open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year. Proper understanding resource allocation is important in minimizing the effect of Friedreich's Ataxia on people's lives while maximizing their quality of life.
Impact of Friedreich's Ataxia on health-care resource utilization in the United Kingdom and Germany. Paola Giunti, Julia Greenfield, Alison J Stevenson, Michael H Parkinson, Jodie L Hartmann, Ruediger Sandtmann, James Piercy, Jamie O'Hara, Leo Ruiz Casas and Fiona M Smith, Orphanet Journal of Rare Diseases 2013, 8:38 doi:10.1186/1750-1172-8-38
What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central's open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year. Proper understanding resource allocation is important in minimizing the effect of Friedreich's Ataxia on people's lives while maximizing their quality of life.
Impact of Friedreich's Ataxia on health-care resource utilization in the United Kingdom and Germany. Paola Giunti, Julia Greenfield, Alison J Stevenson, Michael H Parkinson, Jodie L Hartmann, Ruediger Sandtmann, James Piercy, Jamie O'Hara, Leo Ruiz Casas and Fiona M Smith, Orphanet Journal of Rare Diseases 2013, 8:38 doi:10.1186/1750-1172-8-38
Wednesday, February 27, 2013
Santhera to Discontinue Sale of Catena® in Canada
Santhera to Discontinue Sale of Catena® in Canada. 12:40 EST 27 Feb 2013 | Thomson Reuters.
Liestal, Switzerland, February 27, 2013 - Santhera Pharmaceuticals (SIX: SANN) announced today the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich's Ataxia, and subsequent consultation with Health Canada.
Santera's web page
Liestal, Switzerland, February 27, 2013 - Santhera Pharmaceuticals (SIX: SANN) announced today the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich's Ataxia, and subsequent consultation with Health Canada.
Santera's web page
Monday, February 25, 2013
White House announces new US open access policy
White House announces new US open access policy. Newsblog (nature.com), 22 Feb 2013, Posted by Richard Van Noorden.
In a long-awaited leap forward for open access, the US government said today that publications from taxpayer-funded research should be made free to read after a year’s delay – expanding a policy which until now has only applied to biomedical science.
With both the US and Europe supporting delayed-access to publications, the UK government looks increasingly isolated in its preference for immediate open access. That policy is due to come in from 1 April, but the details are not yet clear. Communication around the policy was yesterday criticized as “unacceptable” by a House of Lords inquiry.
In a long-awaited leap forward for open access, the US government said today that publications from taxpayer-funded research should be made free to read after a year’s delay – expanding a policy which until now has only applied to biomedical science.
With both the US and Europe supporting delayed-access to publications, the UK government looks increasingly isolated in its preference for immediate open access. That policy is due to come in from 1 April, but the details are not yet clear. Communication around the policy was yesterday criticized as “unacceptable” by a House of Lords inquiry.
Sunday, February 24, 2013
Very late-onset Friedreich ataxia: later than life expectancy?
Very late-onset Friedreich ataxia: later than life expectancy?. Vincent Alvarez, Pierre Arnold, Thierry Kuntzer; Journal of Neurology February 2013. DOI:10.1007/s00415-013-6874-6
Saturday, February 23, 2013
Mitochondrial Transport, Metabolism and ROS Production in Disease Models
Mitochondrial Transport, Metabolism and ROS Production in Disease Models. Peter Hollenbeck, reearch talk in the Samuel Colella Lecture Series in Neurodegeneration at the Institute for Neurodegenerative Diseases of the University of Pittsburgh School of Medicine.
The talk covered studies from the Hollenbeck laboratory on the etiology of Friedreich ataxia and Parkinson’s disease. The work implicates defects in axonal transport, metabolism and mitochondrial turnover in the death of neurons.
The talk covered studies from the Hollenbeck laboratory on the etiology of Friedreich ataxia and Parkinson’s disease. The work implicates defects in axonal transport, metabolism and mitochondrial turnover in the death of neurons.
Thursday, February 21, 2013
Job opportunity. Study of the role of glial cells and neurons-glia interactions in Alzheimer disease and Friedreich ataxia
Job opportunity. Study of the role of glial cells and neurons-glia interactions in Alzheimer disease and Friedreich ataxia. UNIVERSITE PARIS
Identification of physiopathological mechanisms in human degenerative pathologies and new therapeutic compounds using Drosophila and mice. Study of the role of glial cells and neurons-glia interactions in Alzheimer disease and Friedreich ataxia using approaches from genetics to behavioral studies
Identification of physiopathological mechanisms in human degenerative pathologies and new therapeutic compounds using Drosophila and mice. Study of the role of glial cells and neurons-glia interactions in Alzheimer disease and Friedreich ataxia using approaches from genetics to behavioral studies
Tuesday, February 19, 2013
Discovery in HIV May Solve Efficiency Problems for Gene Therapy
Discovery in HIV May Solve Efficiency Problems for Gene Therapy. Case Western Reserve University (2013, February 14). Discovery in HIV may solve efficiency problems for gene therapy.
Journal Reference:
Mastooreh Chamanian, Katarzyna J. Purzycka, Paul T. Wille, Janice S. Ha, David McDonald, Yong Gao, Stuart F.J. Le Grice, Eric J. Arts. A cis-Acting Element in Retroviral Genomic RNA Links Gag-Pol Ribosomal Frameshifting to Selective Viral RNA Encapsidation. Cell Host & Microbe, 2013; 13 (2): 181 DOI: 10.1016/j.chom.2013.01.007
Journal Reference:
Mastooreh Chamanian, Katarzyna J. Purzycka, Paul T. Wille, Janice S. Ha, David McDonald, Yong Gao, Stuart F.J. Le Grice, Eric J. Arts. A cis-Acting Element in Retroviral Genomic RNA Links Gag-Pol Ribosomal Frameshifting to Selective Viral RNA Encapsidation. Cell Host & Microbe, 2013; 13 (2): 181 DOI: 10.1016/j.chom.2013.01.007
“Generación de Un Modelo Experimental Humano de Ataxia de Friedreich Mediante Células Troncales Pluripotentes Inducidas (Ipsc)”
“Generación de Un Modelo Experimental Humano de Ataxia de Friedreich Mediante Células Troncales Pluripotentes Inducidas (Ipsc)”. "Offer of employment"
El proyecto “Generación de Un Modelo Experimental Humano de Ataxia de Friedreich Mediante Células Troncales Pluripotentes Inducidas (Ipsc)” es un proyecto financiado a través de la convocatoria de la Consejería de Salud y Bienestar Social del año 2010, con número de expediente 726/2010.
El proyecto “Generación de Un Modelo Experimental Humano de Ataxia de Friedreich Mediante Células Troncales Pluripotentes Inducidas (Ipsc)” es un proyecto financiado a través de la convocatoria de la Consejería de Salud y Bienestar Social del año 2010, con número de expediente 726/2010.
Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy
Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy. Chiranjeevi Sandi, Sahar Al-Mahdawi, and Mark A. Pook. Genetics Research International, Volume 2013 (2013), Article ID 852080, 12 pages. http://dx.doi.org/10.1155/2013/852080
OPEN ACCESS
OPEN ACCESS
Subscribe to:
Posts (Atom)
